4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-pyrrolidinyl]-1-(tetrahydro-2H-pyran-4-yl)-

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-pyrrolidinyl]-1-(tetrahydro-2H-pyran-4-yl)-
• 英文别名: 6-(1-benzyl-4-methylpyrrolidin-3-yl)-1-(oxan-4-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
• 化学式: C₂₂H₂₇N₅O₂
• 分子量: 393.5
• InChiKey: RVEJWGYZBXCGGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Verhoest Patrick R.

  公开号：US20090030003A1

  公开（公告）日：2009-01-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  该发明提供了式（I）的PDE9抑制化合物及其药用盐，其中R、R1、R2和R3如本文所定义。还提供了含有式I化合物的药物组合物，并将其用于治疗神经退行性和认知障碍，如阿尔茨海默病和精神分裂症。
• NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA

  公开号：US20160002246A1

  公开（公告）日：2016-01-07

  It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B 1 is a radical selected from the group consisting of formula (A″), formula (B″), formula (C″), and formula (D″):

  它涉及到一些具有多环结构和羟胺酸基团的化合物，其中多环结构包括至少三个环系统，其中一个环系统是由2至4个环组成的多环环系统；至少一个环是芳香环；结构中包含至少3个氮原子和1个氧原子。它还涉及到它们的制备过程，以及包含它们的制药组合物，以及它们在医学上的应用，特别是在治疗和/或预防伴随认知缺陷或损伤或神经退行性疾病的神经系统疾病中。其中B1是从公式（A''）、公式（B''）、公式（C''）和公式（D''）组成的基团。
• US7964607B2
  申请人：——

  公开号：US7964607B2

  公开（公告）日：2011-06-21
• US9573956B2
  申请人：——

  公开号：US9573956B2

  公开（公告）日：2017-02-21
• [EN] AMINO-HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS AMINO-HÉTÉROCYCLIQUES
  申请人：PFIZER

  公开号：WO2008139293A1

  公开（公告）日：2008-11-20

  [EN] The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R₁, R₂ and R₃ are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
  [FR] L'invention porte sur des composés inhibant PDE9 de Formule (I) et sur des sels pharmaceutiquement acceptables de ceux-ci, où R, R₁, R₂ et R₃ sont tels que définis présentement. L'invention porte également sur des compositions pharmaceutiques contenant les composés de Formule I et sur les utilisations de celles-ci dans le traitement de troubles neurodégénératifs et cognitifs, tels que la maladie d'Alzheimer et la schizophrénie.